Atomo Diagnostics (ASX:AT1) said its strategic partner Lumos Diagnostics (ASX:LDX) placed an order with the company for the supply of $410,000 worth of Pascal cassettes to support scaling up the demand for the company's diagnostic product, FebriDx, in the US market, according to a Thursday Australian bourse filing.
The company said that Lumos indicated that it expects the agreement with Phase to generate FebriDx product sales of up to $316 million over six years, assuming that the clinical laboratory improvement amendments (CLIA) waiver is granted and contracted minimum order quantities are achieved.
The FebriDx test secured a 510k clearance from the US Food and Drug Administration and is currently well progressed through a CLIA waiver study that is expected to be completed this month.
Atomo Diagnostics' shares fell 5% in recent Thursday trade. Lumos Diagnostics' shares jumped almost 6%, earlier hitting their highest since September 2023.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。